Cargando…
Plant Platforms for Efficient Heterologous Protein Production
Production of recombinant proteins is primarily established in cultures of mammalian, insect and bacterial cells. Concurrently, concept of using plants to produce high-value pharmaceuticals such as vaccines, antibodies, and dietary proteins have received worldwide attention. Newer technologies for p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Biotechnology and Bioengineering
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346785/ https://www.ncbi.nlm.nih.gov/pubmed/34393545 http://dx.doi.org/10.1007/s12257-020-0374-1 |
_version_ | 1783734950412943360 |
---|---|
author | Ghag, Siddhesh B. Adki, Vinayak S. Ganapathi, Thumballi R. Bapat, Vishwas A. |
author_facet | Ghag, Siddhesh B. Adki, Vinayak S. Ganapathi, Thumballi R. Bapat, Vishwas A. |
author_sort | Ghag, Siddhesh B. |
collection | PubMed |
description | Production of recombinant proteins is primarily established in cultures of mammalian, insect and bacterial cells. Concurrently, concept of using plants to produce high-value pharmaceuticals such as vaccines, antibodies, and dietary proteins have received worldwide attention. Newer technologies for plant transformation such as plastid engineering, agroinfiltration, magnifection, and deconstructed viral vectors have been used to enhance the protein production in plants along with the inherent advantage of speed, scale, and cost of production in plant systems. Production of therapeutic proteins in plants has now a more pragmatic approach when several plant-produced vaccines and antibodies successfully completed Phase I clinical trials in humans and were further scheduled for regulatory approvals to manufacture clinical grade products on a large scale which are safe, efficacious, and meet the quality standards. The main thrust of this review is to summarize the data accumulated over the last two decades and recent development and achievements of the plant derived therapeutics. It also attempts to discuss different strategies employed to increase the production so as to make plants more competitive with the established production systems in this industry. |
format | Online Article Text |
id | pubmed-8346785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Society for Biotechnology and Bioengineering |
record_format | MEDLINE/PubMed |
spelling | pubmed-83467852021-08-09 Plant Platforms for Efficient Heterologous Protein Production Ghag, Siddhesh B. Adki, Vinayak S. Ganapathi, Thumballi R. Bapat, Vishwas A. Biotechnol Bioprocess Eng Review Paper Production of recombinant proteins is primarily established in cultures of mammalian, insect and bacterial cells. Concurrently, concept of using plants to produce high-value pharmaceuticals such as vaccines, antibodies, and dietary proteins have received worldwide attention. Newer technologies for plant transformation such as plastid engineering, agroinfiltration, magnifection, and deconstructed viral vectors have been used to enhance the protein production in plants along with the inherent advantage of speed, scale, and cost of production in plant systems. Production of therapeutic proteins in plants has now a more pragmatic approach when several plant-produced vaccines and antibodies successfully completed Phase I clinical trials in humans and were further scheduled for regulatory approvals to manufacture clinical grade products on a large scale which are safe, efficacious, and meet the quality standards. The main thrust of this review is to summarize the data accumulated over the last two decades and recent development and achievements of the plant derived therapeutics. It also attempts to discuss different strategies employed to increase the production so as to make plants more competitive with the established production systems in this industry. The Korean Society for Biotechnology and Bioengineering 2021-08-07 2021 /pmc/articles/PMC8346785/ /pubmed/34393545 http://dx.doi.org/10.1007/s12257-020-0374-1 Text en © The Korean Society for Biotechnology and Bioengineering and Springer 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Paper Ghag, Siddhesh B. Adki, Vinayak S. Ganapathi, Thumballi R. Bapat, Vishwas A. Plant Platforms for Efficient Heterologous Protein Production |
title | Plant Platforms for Efficient Heterologous Protein Production |
title_full | Plant Platforms for Efficient Heterologous Protein Production |
title_fullStr | Plant Platforms for Efficient Heterologous Protein Production |
title_full_unstemmed | Plant Platforms for Efficient Heterologous Protein Production |
title_short | Plant Platforms for Efficient Heterologous Protein Production |
title_sort | plant platforms for efficient heterologous protein production |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346785/ https://www.ncbi.nlm.nih.gov/pubmed/34393545 http://dx.doi.org/10.1007/s12257-020-0374-1 |
work_keys_str_mv | AT ghagsiddheshb plantplatformsforefficientheterologousproteinproduction AT adkivinayaks plantplatformsforefficientheterologousproteinproduction AT ganapathithumballir plantplatformsforefficientheterologousproteinproduction AT bapatvishwasa plantplatformsforefficientheterologousproteinproduction |